Publications

NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in PDAC

AM Schram, SR Yang, M Repetto, R Velasco, G Kahn, R Do, S Dinapoli, ...

Obesity and biliary tract cancers: Changing epidemiology.

L Al Mahmasani, JF Chou, M Capanu, A Srivastava, CS Sigel, ...

OR19-06 Safety and Effectiveness of Sulfonylureas for Pancreas-Cancer Induced Metabolic Dysregulation

JH Flory, H Martirosova, E Tan, M Bakkar, M Goncalves, W Park, ...

Orally administered MOMA-313 as monotherapy or combination therapy in participants with advanced or metastatic solid homologous recombination (HR) deficient tumors: Phase 1 …

A Patnaik, W Abida, KA Reiss, J De Bono, R McKay, AH Bryce, ...

PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer

Knox JJ, O'Kane G, King D, Laheru D, Habowski AN, Yu K, Perez K, Aguirre AJ, et al.

Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

AN Habowski, H Patel, C Tsang, L St. Surin, D Plenker, FM Kouassi, ...

Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial

Park W, O'Connor C, Chou J, Hilmi M, Tarcan Z, Schwartz C, Larsen M, Chatila W, et al.

Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors

JA Chan, S Geyer, T Zemla, MV Knopp, S Behr, S Pulsipher, FS Ou, ...

Phase II Study of Pexidartinib Plus Sirolimus in Unresectable Malignant Peripheral Nerve Sheath Tumors Identifies M2 Macrophage Activation

Manji GA, Stanton LJ, Hirbe AC, Ge L, Sta Ana S, Titus S, Labadie BW, May MS, et al.

Plant-based diet and survival among patients with metastatic colorectal cancer

E Cheng, FS Ou, C Gatten, C Ma, AP Venook, HJ Lenz, EM O’Reilly, ...

Prognostic and predictive role of circulating tumor DNA (ctDNA) in stage III colon cancer treated with celecoxib: Findings from CALGB (Alliance)/SWOG 80702.

JA Nowak, Q Shi, T Twombly, LD Pederson, C Ma, JP Vaeyrynen, ...

Prognostic and predictive role of T cell infiltration in stage III colon cancer (CC) treated with celecoxib: CALGB/SWOG 80702

Y Takashima, C Ma, Q Shi, AD Costa, T Twombly, JP Väyrynen, M Zhao, ...

Radiomic signatures to estimate survival in patients with advanced hepatocellular carcinoma treated with sorafenib: Cancer and Leukemia Group B 80802 (Alliance)

L Dercle, S Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, L Luk, ...

Randomized phase II trial of olaparib+ pembrolizumab vs olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer with germline BRCA1 or BRCA2 …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, D Sohal, KA Reiss, ...

Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)

Bergsland EK, Geyer S, Asmis TR, Behr SC, Kuebler JP, Kumthekar P, Mazza G, Maitland ML, et al.

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer …

FA Sinicrope, FS Ou, D Arnold, W Peters, RJ Behrens, CH Lieu, K Matin, ...

Redefining phenotypic intratumor heterogeneity of pancreatic ductal adenocarcinoma: a bottom-up approach

Hilmi M, Delecourt F, Raffenne J, Bourega T, Dusetti N, Iovanna J, Blum Y, Richard M, et al.

Resistance mechanisms to monotherapy RAS (ON) multi-selective inhibitor daraxonrasib (RMC-6236) in RAS mutant PDAC inform therapeutic combination strategies

I Aronchik, S Kar, Y Zhuang, E Ahler, LP Lai, V Seshadri, A Starodub, ...

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Sethna Z, Guasp P, Reiche C, Milighetti M, Ceglia N, Patterson E, Lihm J, …

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with …

I Garrido-Laguna, BM Wolpin, W Park, NS Azad, AI Spira, A Starodub, ...

Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702)(Alliance).

E Cheng, Q Shi, AF Shields, C Kuang, A Shergill, C Ma, KA Guthrie, ...

Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)

Cheng E, Shi Q, Shields AF, Xue X, Rohan TE, Kuang C, Shergill AP, Ma C, et al.

Survival in Young-Onset Metastatic Colorectal Cancer: Findings From Cancer and Leukemia Group B (Alliance)/SWOG 80405 (vol 114, pg 427, 2021)

M Lipsyc-Sharf, S Zhang, FS Ou, C Ma, NJ McCleary, D Niedzwiecki, ...

Survival of patients with resected microsatellite instability-high, mismatch repair deficient, and lynch syndrome-associated pancreatic ductal adenocarcinomas

EL Eikenboom, N Nasar, K Seier, M Gönen, MCW Spaander, EM O’Reilly, ...

Survival Outcomes and Genetic Characteristics of Resected Pancreatic Acinar Cell Carcinoma

Blair AB, Radomski SN, Chou J, Liu M, Howell TC, Park W, O'Reilly EM, Zheng L, et al.

Target identification for antibody-drug-conjugate (ADC) therapy in biliary tract cancers (BTC)

A Dhyani, Z Tarcan, J Chou, R Thummalapalli, W Chatila, S Nag, E Rosen, ...

The Noncoding Mutational Landscape of Pancreatic Cancer Reveals Recurrent Somatic Mutations in Enhancer Regions

Hayashi A, Ho YJ, Makohon-Moore AP, Zucker A, Hong J, Umeda S, Karnoub ER, Huang J, et al.

Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches

Song J, Gersten A, Herzberg B, Halmos B

Toward Early Detection: A Scoping Review of Hepatocellular Cancer Surveillance in Sub-Saharan Africa

S Okeke, O Adewara, D Akoki, I Ijezie, M Abraham, D Irabor, F Balogun

Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS (ON) multi-selective inhibitor, versus standard …

BM Wolpin, ZA Wainberg, I Garrido-Laguna, GA Manji, AI Spira, NS Azad, ...

Trials in progress: Alliance A022104/NRG-GI010—A randomized phase II/III trial testing the efficacy of triplet versus doublet chemotherapy regarding clinical complete response …

CS Kitchens, Q Shi, A Dasari, J Garcia-Aguilar, HK Sanoff, TJ George, ...

Tu1375: INCIDENCE OF PANCREATIC ADENOCARCINOMA AND NEOPLASTIC PROGRESSION DURING IMAGING SURVEILLANCE IN HIGH-RISK INDIVIDUALS FOR PANCREATIC CANCER

SE Lee, MA Schattner, J Naduparambil, K O’Connell, N Peeri, P Wang, ...

Utilizing Patient Input in Rectal Cancer Trial Design

Alvarez J, Zambare W, George M, Garcia R, Gallagher P, Kitchens C, Bercz A, Kim MJ, et al.

1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including …

J Chan, S Geyer, T Zemla, MV Knopp, SC Behr, S Pulsipher, J Acoba, ...

1504MO Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination …

W Park, C O’Connor, J Chou, C Schwartz, M Larsen, A Varghese, K Yu, ...

1532TiP Zolbetuximab with gemcitabine+ nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized …

W Park, EM O'Reilly, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

317P Targeted next generation sequencing (NGS) of cell free (cf) DNA in biliary tract cancer (BTC)

D Cowzer, K Seier, M Darmofal, P Shin, D Khalil, H Walch, J Shia, W Park, ...

323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+ NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): subgroup analysis of …

TM Mercade, RAP Cid, M Womack, AC Gracian, A Zervoudakis, ...

592 CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): updated efficacy and correlative biomarkers from …

KP Geboes, G Beatty, I Borbath, T Macarulla, A Lambert, P Cassier, ...

708 Chemoimmunotherapy (ChemoIO) as treatment for pancreatic neuroendocrine carcinoma: survival outcomes and immunogenomic analysis

D Moss, C O’Connor, Z Tarcan, T Kim, MA Perry, R Thummalapalli, ...

A multi-institutional randomized phase III trial of chemotherapy alone versus chemotherapy and ablative 5-fraction MRI-guided adaptive radiation therapy for locally advanced …

MD Chuong, JM Frakes, KE Mittauer, J Good, J Kim, D Chang, DW Kim, ...

A Somatic BRCA2-Mutated Pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX

Jamison JK, May MS, Raufi AG, Luk L, Wong W, Mundi PS, Manji GA

Abstract A005: A multi-institutional randomized phase III trial of chemotherapy alone versus chemotherapy and ablative 5-fraction MRI-guided adaptive radiation therapy for …

MD Chuong, JM Frakes, KE Mittauer, J Good, J Kim, D Chang, DW Kim, ...

Abstract B042: Clinical and molecular characterization of Lynch syndrome-associated pancreas adenocarcinoma (PDAC)

E Harrold, CA O'Connor, D Lin, A Gazzo, H Walch, M Ranganathan, ...

Abstract B045: Deep genomic and single cell molecular profiles define immunogenic pancreatic cancer

W Park, S Umeda, C O'Connor, H Zhang, R Sharma, A Richards, Y Zhu, ...

Abstract B061: Phase 1b study of maintenance soluble beta-glucan (Odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic …

MH O'Hara, M Wattenberg, I Garrido-Laguna, EM O'Reilly, M Yellin, ...

Abstract C074: Clinico-genomic characterization of N=2,460 pancreatic adenocarcinoma identifies KRASMUT dosage as prognostic of overall survival across …

AM Varghese, MA Perry, D Muldoon, S Nandakumar, A Erakky, B Nguyen, ...

Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in …

ZA Wainberg, S Pant, CD Weekes, M Furqan, PM Kasi, CE Devoe, ...

Abstract C104: Dual primary pancreas cancers–Related or independent lesions?

JD Schoenfeld, H Sahan-Ozkan, N Bilani, MI D'Angelica, WR Jarnagin, ...

Abstract PR-06: Personalized RNA neoantigen vaccines induce long-lived CD8+ T effector cells in pancreatic cancer

P Guasp, Z Sethna, C Reiche, M Milighetti, N Ceglia, E Patterson, N Pang, ...